Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongling Peng

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Heliyon|August 14, 2023
Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphomaShicong Zhu, Yan Zhao, Cheng Xing, et al.
Carcinogenesis|June 21, 2024
Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic targetShiying Lei, Jiajun Sun, Yifang Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|December 7, 2024
Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trialKaiyang Ding, Hailing Liu, Lixia Sheng, et al.
Annals of Hematology|July 6, 2021
Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasmsLe Yin, Sisi Xie, Yi Chen, et al.
Blood Cancer Journal|April 29, 2025
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphomaLixia Sheng, Hailing Liu, Xiaohui Zhang, et al.
Haematologica|January 26, 2023
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trialKaiyang Ding, Hailing Liu, Jie Ma, et al.
Oncogene|December 9, 2024
Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progressionHaiqin Wang, Long Liang, Yifang Xie, et al.
Cancer Gene Therapy|July 8, 2020
An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathwayJingyao Chen, Lei Zhao, Hongling Peng, et al.
Cell Death & Disease|September 11, 2020
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1<sup>-</sup> pre-B-ALLZhihua Wang, Yang Zhang, Shicong Zhu, et al.
Pharmaceuticals (Basel, Switzerland)|June 24, 2022
HIF-PH Encoded by <i>EGLN1</i> Is a Potential Therapeutic Target for Chronic Lymphocytic LeukemiaWancheng Guo, Daomiao Liang, Peilong Wang, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Heliyon|August 14, 2023
Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphomaShicong Zhu, Yan Zhao, Cheng Xing, et al.
Carcinogenesis|June 21, 2024
Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic targetShiying Lei, Jiajun Sun, Yifang Xie, et al.
European Journal of Cancer (Oxford, England : 1990)|December 7, 2024
Anti-PD-1 antibody (Tislelizumab) combined with gemcitabine and oxaliplatin for extranodal NK/T-cell lymphoma failing asparaginase: A multicenter phase II trialKaiyang Ding, Hailing Liu, Lixia Sheng, et al.
Annals of Hematology|July 6, 2021
Novel germline mutation KMT2A G3131S confers genetic susceptibility to familial myeloproliferative neoplasmsLe Yin, Sisi Xie, Yi Chen, et al.
Blood Cancer Journal|April 29, 2025
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphomaLixia Sheng, Hailing Liu, Xiaohui Zhang, et al.
Haematologica|January 26, 2023
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trialKaiyang Ding, Hailing Liu, Jie Ma, et al.
Oncogene|December 9, 2024
Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progressionHaiqin Wang, Long Liang, Yifang Xie, et al.
Cancer Gene Therapy|July 8, 2020
An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathwayJingyao Chen, Lei Zhao, Hongling Peng, et al.
Cell Death & Disease|September 11, 2020
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1<sup>-</sup> pre-B-ALLZhihua Wang, Yang Zhang, Shicong Zhu, et al.
Pharmaceuticals (Basel, Switzerland)|June 24, 2022
HIF-PH Encoded by <i>EGLN1</i> Is a Potential Therapeutic Target for Chronic Lymphocytic LeukemiaWancheng Guo, Daomiao Liang, Peilong Wang, et al.
Pageof 11